|
Tumor Progression
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
3MC increased AhR binding to promoter regions of genes involved in Notch signaling (Hes1, Jag1), activation of primordial follicles (Cdk2), cell adhesion (Icam1), stress and tumor progression (Dnajb6), apoptosis (Bax, Caspase-9) and expression of growth and transcription factors (Igf2, Sp1).
|
29094188 |
2018 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
5-fluorouracil (5-Fu) chemoresistance was examined in CRC cell lines (RKO and HCT8, LOVO) with stable over-expression and inhibition of HES1 gene by cytotoxicity test.
|
28928869 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor development was associated with activation of Notch pathway, as evidenced by upregulation of Hes-1.
|
15531924 |
2004 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CRC cell lines were used to analyse the control of Hes1 and Atoh1 by β-catenin signalling.
|
21205878 |
2011 |
|
Malignant tumor of colon
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Colon cancer cell lines which over-expressed HES1 were more resistant to 5-Fu treatment <i>in vitro</i>.
|
28928869 |
2017 |
|
Colon Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Colon cancer cell lines which over-expressed HES1 were more resistant to 5-Fu treatment <i>in vitro</i>.
|
28928869 |
2017 |
|
Adenoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
HES1 protein was strongly expressed in 18/19 ovarian cancers and borderline tumours but not in adenomas.
|
16136053 |
2005 |
|
Hepatoblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
HES1 expression and HES1/AXIN2 used to measure Notch versus Wnt activation ratio were particularly elevated in pure fetal cases and were lowest in hepatoblastomas with small-cell component.
|
19200579 |
2009 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
HES-1, a downstream target of Notch signaling, is shown to be decreased in human HCC cell line SMMC7721 with RUNX3 gene transfection.
|
19800882 |
2010 |
|
Rhabdomyosarcoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
HES1 is highly expressed in rhabdomyosarcomas, and the inhibition of HES1 restores differentiation in these cells.
|
20022559 |
2010 |
|
Leukemia, T-Cell
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Hes1 expression and CYLD repression are essential events downstream of Notch1 in T-cell leukemia.
|
21389783 |
2011 |
|
Marijuana Abuse
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Hairy and enhancer of split 1 (Hes1) and Hes5 are target genes for the mammalian Notch pathway, which are highly expressed in epithelia in the process of embryogenesis or in neural stem cells, inhibit cell differentiation via the Notch-Hes-Hash signaling, and promote the survival of stem cells.
|
21495212 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HES1 mRNA expression was elevated in tumor samples relative to normal bone, but decreased in tumor samples from dogs with a DFI < 100 days relative to those with a DFI > 300 days.
|
23816051 |
2013 |
|
Medulloblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
HES1 was identified as a direct target of microRNA-9 in medulloblastoma, and restoration of microRNA-9 was shown to trigger cell cycle arrest, to inhibit clonal growth and to promote medulloblastoma cell differentiation.
|
24346283 |
2014 |
|
Childhood Medulloblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
HES1 was identified as a direct target of microRNA-9 in medulloblastoma, and restoration of microRNA-9 was shown to trigger cell cycle arrest, to inhibit clonal growth and to promote medulloblastoma cell differentiation.
|
24346283 |
2014 |
|
Adult Medulloblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
HES1 was identified as a direct target of microRNA-9 in medulloblastoma, and restoration of microRNA-9 was shown to trigger cell cycle arrest, to inhibit clonal growth and to promote medulloblastoma cell differentiation.
|
24346283 |
2014 |
|
leukemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.
|
24486648 |
2014 |
|
Childhood Leukemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.
|
24486648 |
2014 |
|
Blast Phase
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.
|
24486648 |
2014 |
|
Blast Phase
|
0.030 |
Biomarker
|
disease |
BEFREE |
Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells.
|
24825862 |
2014 |
|
Myeloid Leukemia, Chronic
|
0.230 |
Biomarker
|
disease |
BEFREE |
Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells.
|
24825862 |
2014 |
|
Basal-Like Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer.
|
25541438 |
2015 |
|
Pancreatic carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer.
|
25672829 |
2015 |
|
Malignant neoplasm of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer.
|
25672829 |
2015 |
|
Recurrent tumor
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Hes-1 has potential prognostic value in post-surgical HCC patients and may be an independent prognostic indicator for overall survival and tumor recurrence.
|
25987042 |
2015 |